

## Press Release

Zug, 25 June 2010

### **Shareholders' meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM BioVentures shares and intensify cooperation**

At today's ordinary shareholders' meeting, the shareholders of HBM BioVentures Ltd approved all of the proposals submitted by the Board of Directors.

The Board of Directors of HBM BioVentures now comprises 5 members: Hans Peter Hasler (Chairman), Prof. Heinz Riesenhuber (Vice-Chairman), Dr. Eduard E. Holdener, Robert A. Ingram and Dr. Rudolf Lanz.

Dr. Henri B. Meier and Prof. Ulrich Abshagen did not stand for re-election. The shareholders' meeting thanked them for their significant efforts for the HBM Group over the past 9 years. The Board of Directors elected Dr. Henri B. Meier as its honorary Chairman.

The Board of Directors appointed Hans Peter Hasler as its new Chairman. Mr Hasler has been a member of the HBM BioVentures Board of Directors since 2009, prior to which he was Chief Operating Officer at Biogen Idec, one of the world's largest biotechnology firms.

Astellas, the international pharmaceuticals company with its head office in Tokyo that recently acquired OSI Pharmaceuticals, confirmed that it will not only retain the 10.5% equity stake in HBM BioVentures, but will also seek to further step up its cooperation with HBM.

#### **Reduction of share capital**

The shareholders' meeting approved the reduction of the share capital to CHF 612,000,000 by cancelling 500,000 registered shares with a par value of CHF 60 each. Following the corresponding entry in the Commercial Register, there will therefore be 10,200,000 registered shares with a par value of CHF 60 each outstanding.

### **New calculation basis for the management fee**

HBM BioVentures has agreed with its investment advisor HBM Partners to amend the calculation basis for the management fee of 1.5% p.a. as follows from 1 April 2011: 80% of the management fee will be calculated on the basis of the company's assets, 20% on the basis of its market capitalisation. To date, the fee has been calculated fully on the basis of the company's assets. All the other regulations remain unchanged.

### **Amended investment guidelines**

The Board of Directors of HBM BioVentures has amended the investment guidelines of the company in line with the decisions on its strategy announced on 3 May 2010. The new investment guidelines have been published on the company's website at [www.hmbioventures.com](http://www.hmbioventures.com).

### **Contact**

For further information, please contact Dr Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, [andreas.wicki@hmbioventures.com](mailto:andreas.wicki@hmbioventures.com).

### **Portrait of Hans Peter Hasler, Chairman of the Board of Directors of HBM BioVentures Ltd**



Hans Peter Hasler (54). Having worked with the Basle-based Sanofi Pharma AG and Abbott Ltd in Zug, Hans Peter Hasler's career took him to Wyeth Group, where he held various senior management positions in Switzerland, Europe and the USA. Between 2001 and 2009, he worked for various companies in the Biogen Group, latterly as Chief Operating Officer of the US firm Biogen Idec Inc., which is based in Cambridge, USA, where he had overall responsibility for the worldwide business, business development, medical affairs and Biogen International. Since this year, he has been working as an independent consultant to biotech and pharmaceuticals companies. Hans Peter Hasler has been Vice-Chairman of the Board of Directors of Santhera Pharmaceuticals Holding Ltd (SIX: SANN) since 2006, and of Acino Pharma AG (SIX: ACIN) since 2008. He holds a Swiss Federal Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business and Economics (SIB) in Zurich.

### **Brief profile of HBM BioVentures Ltd**

As a venture capital company, HBM BioVentures invests world-wide in some 35 mature young companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of many of HBM BioVentures' portfolio

**NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA**



companies are either at an advanced stage of development or already available on the market. The investment focus is on emerging companies that are not yet public. Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

**Disclaimer**

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

**HBM BioVentures AG**  
Bundesplatz 1  
CH-6300 Zug/ Switzerland  
Tel:+41 41 768 11 08  
Fax:+41 41 768 11 09  
[info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)